PROCESSA PHARMACEUTICALS ANNOUNCES LAST PATIENT ENROLLED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA
August 26, 2019 09:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo
July 30, 2019 08:30 ET
|
Auris Medical AG
Hamilton, Bermuda, July 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer
October 09, 2018 10:00 ET
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...